Trials / Completed
CompletedNCT02321111
The Role of TLR4 on Lipid-induced Insulin Resistance
The Role of TLR4 on Lipid-Induced Insulin Resistance
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) prevents lipid-induced insulin resistance in lean, normal glucose tolerant (NGT) subjects.
Detailed description
E5564 = Eritoran
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eritoran | Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4. |
| DRUG | D5W (5% Dextrose in water) | D5W = 5% Dextrose Water Vehicle |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2018-09-01
- Completion
- 2018-09-01
- First posted
- 2014-12-22
- Last updated
- 2019-10-08
- Results posted
- 2019-10-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02321111. Inclusion in this directory is not an endorsement.